Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Calliditas Therapeutics in connection with the listing on Nasdaq Stockholm’s main market
Mandate

Vinge advises Calliditas Therapeutics in connection with the listing on Nasdaq Stockholm’s main market

June 29, 2018 Capital Markets and Public M&A

Vinge advises Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) in connection with the listing of the company’s shares on Nasdaq Stockholm’s main market. Trading in Calliditas Therapeutics’ shares on Nasdaq Stockholm commences today, 29 June 2018.

The price in the offering was set at SEK 45 per share, which corresponds to a value of the total number of shares in the company upon completion of the offering of SEK 1,593 million, assuming full exercise of the over-allotment option in the offering. Assuming full exercise of the over-allotment option, the value of the offering amounts to approximately SEK 747 million before transaction costs. 

Calliditas is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy.
  
Vinge’s team primarily consists of Dain Hård Nevonen, Johan Larsson, Maria Schultzberg, Sofie Bjärtun, Sabina Kihlberg, Filip Öhrner, Victor Ericsson and William Kåge. 

Related

Vinge has advised Main Capital and Pointsharp in connection with the acquisition of Meaplus AB and Nubibus Software AB

 Vinge has advised Main Capital and its portfolio company Pointsharp in connection with Pointsharp's acquisition of Meaplus AB and Nubibus Software AB. Pointsharp is a Swedish provider of identity and access management solutions as well as secure information exchange, with operations in the Nordics, DACH and Benelux. The acquisition complements Pointsharp's existing offering with capabilities in secure digital communication and strengthens the company's position in the Swedish public-sector market, particularly in the municipal and healthcare segments. The transaction is Pointsharp's sixth add-on acquisition since Main Capital became an investment partner in November 2020.
October 01, 2026

Vinge has advised Main Capital Partners on the acquisition of Confirma Software

 Confirma Software (“Confirma”) is a Nordic vertical software group providing mission-critical B2B software to SMEs in Sweden, Finland, Norway and Denmark. The company operates across five complementary software areas: ERP, Payment Solutions, Financial Solutions, Quality Management Systems and Business Process Solutions. Confirma was founded in 2019 and is headquartered in Stockholm. Supported by approximately 540 professionals, the company serves more than 25,000 customers, including over 500 municipalities, across the Nordics. By combining deep local domain expertise with software embedded in customers’ day-to-day operations, Confirma has developed long-standing customer relationships and a highly recurring revenue profile.
September 25, 2026

Vinge has advised Embracer Group in connection with a SEK 2 billion multicurrency revolving credit facility agreement entered into with SEB, DNB, Nordea and Swedbank

 Vinge has advised Embracer Group AB (publ) (“Embracer”) in connection with the entry into of a SEK 2,000,000,000 financing agreement with SEB, DNB, Nordea and Swedbank. Embracer is a global group of entrepreneurial businesses in the gaming and entertainment industry.
September 25, 2026